# BioMarin Pharmaceutical Inc. account plan

> BioMarin is a San Rafael, California rare disease biotech with nine commercial therapies; FY2025 total revenues were $3,221.3 million.

## At a glance

BioMarin Pharmaceutical is a global rare disease biotechnology company founded in 1997 and based in San Rafael, California, developing medicines for genetically defined conditions. It sells through specialty pharmacies, hospitals, government agencies and distributors, with a direct sales force in the U.S., Europe, South America and other significant markets. FY2025 total revenues were $3,221.3 million and net income $348.9 million; it had 3,221 employees at December 31, 2025. After acquiring Amicus Therapeutics on April 27, 2026 it counts nine commercial therapies, grouped as VOXZOGO (Skeletal Conditions) and Metabolic Conditions.

## Business units

- **Skeletal Conditions (VOXZOGO)** ($926.9 million of 2025 net product revenues, about 29% of total revenues): VOXZOGO is a once-daily injected CNP analog for achondroplasia, now treating more than 5 thousand infants and children in 58 countries. Q3 2026 revenue was $245.0 million, up 12%, with more than 75% from outside the U.S. The pipeline adds hypochondroplasia (PDUFA May 30, 2027), BMN 333 and BMN 440.
- **Metabolic Conditions (formerly Enzyme Therapies)** ($2,105.7 million in 2025, about 65% of total revenues): Enzyme and related therapies for rare metabolic diseases: VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME (sold by Sanofi) and BRINEURA, joined in 2026 by GALAFOLD (Fabry) and POMBILITI + OPFOLDA (Pompe) from Amicus. Q3 2026 revenue was $744 million, up 44%.
- **Other products and royalties** (about 6% of total revenues): KUVAN for PKU ($99.6 million in 2025, losing share to generics), ROCTAVIAN, which BioMarin will no longer market, and royalty and other revenues of $53.5 million.

## Strategic priorities

- **Integrate Amicus Therapeutics**: Amicus was acquired on April 27, 2026 for about $5.3 billion; BioMarin expects about $220 million of non-GAAP cost synergies fully realized in 2028, and synergy delivery is ahead of schedule.
- **Extend VOXZOGO beyond achondroplasia**: PDUFA dates of February 28, 2027 for full approval in achondroplasia and May 30, 2027 for hypochondroplasia, an estimated global addressable population of about 14 thousand children.
- **Grow Galafold and Pombiliti + Opfolda**: Drive diagnosis, treatment and switching in Fabry and Pompe; peak revenue of roughly $1 billion each was reiterated, with potential to be higher.
- **Clinical-stage business development**: Five deals in two years, with further deals focused on clinical-stage assets in genetics that fit the Skeletal Conditions and Metabolic Conditions business units.
- **Next-generation pipeline**: BMN 333 (longer-acting CNP aiming for superiority over VOXZOGO), BMN 450 (potential first subcutaneous Fabry enzyme therapy) and BMN 440 (oral therapy for hypophosphatasia, data in 2027).

## Latest results

Q3 2026 total revenues were $1,024.6 million against $776.1 million in Q3 2025, the first quarter above $1 billion in the company's history. The quarter was a net loss of $122.8 million, driven by $287.7 million of acquired IPR&D for BMN 440, $99.5 million of intangible amortization and $55.6 million of interest expense; nine-month net income was $27.5 million. Gross margin was 80.0% (81.9% a year earlier). FY2026 revenue guidance was cut to $3.8-3.9 billion because one international customer intends to defer about $70 million of orders and Middle East customer liquidity has worsened; non-GAAP EPS guidance is $2.80-3.10.

## Investments and deals

- **Amicus Therapeutics acquisition**: Closed April 27, 2026 for about $5.3 billion, funded with the $850.0 million 2034 Notes, term loans and about $1.7 billion of cash; adds GALAFOLD and POMBILITI + OPFOLDA.
- **Alesta Therapeutics acquisition**: Acquired August 31, 2026 for $303.4 million plus up to $215 million of milestones, adding oral BMN 440 for hypophosphatasia.
- **BMN 450 license**: Exclusive worldwide license from GC Biopharma and Hanmi in October 2026 for a long-acting Fabry enzyme therapy: $70.0 million upfront and up to $405.0 million of milestones.
- **Inozyme acquisition and BMN 401**: Inozyme was acquired in July 2025 for $285.2 million net cash; BMN 401 development was discontinued across all indications in August 2026.
- **ROCTAVIAN withdrawal**: Voluntary market withdrawal of the hemophilia A gene therapy decided in December 2025, with about $240.0 million of restructuring charges.

## Challenges and risks

- **Higher debt**: Indebtedness of about $4.2 billion at September 30, 2026, including $600.0 million of convertible notes due May 2027 to refinance, and cash down to $736.0 million.
- **VOXZOGO competition**: A competitor entered the U.S. market in 2026; BioMarin settled all patent litigation with Ascendis in September 2026 in exchange for royalties.
- **Lumpy international orders**: Two thirds of the business is outside the U.S., largely national health systems that order irregularly; one customer's deferral of about $70 million of orders cut 2026 guidance.
- **Pricing and trade pressure**: Government price controls and the Inflation Reduction Act may lower prices; tariffs, currency and Middle East disruption are named risks.
- **Manufacturing and supply**: Reliance on contract manufacturers and sole-source materials; a $31 million charge in Q1 2026 came from an unsuccessful process qualification campaign for NAGLAZYME.

## What leadership says

> "32% year over year growth in the third quarter. Surpassing $1 billion in quarterly revenues for the first time in our history." — Alexander Hardy, Chief Executive Officer, BioMarin Q3 2026 earnings call, 2026-11-02

> "Continue to remain focused on clinical stage deals at the moment" — Alexander Hardy, Chief Executive Officer, BioMarin Q3 2026 earnings call, 2026-11-02

> "this guidance change is not driven by patient demand in these markets." — Brian Mueller, Chief Financial Officer, BioMarin Q3 2026 earnings call, 2026-11-02

> "Our goal with BMN 333 is to evolve this space, not just make a more convenient version" — Gregory Friberg, Chief R&D Officer, BioMarin Q1 2026 earnings call, 2026-05-04


## Where a supplier can help

- **Integration and synergy delivery**: Tied to the Amicus integration and its cost synergy target for 2028: systems consolidation, finance, HR and commercial operations support help merge two organizations.
- **Rare disease diagnosis and patient finding**: Tied to growing Galafold, Pombiliti + Opfolda and VOXZOGO in hypochondroplasia, where diagnosis is the main lever: data, patient-identification and medical education partners fit.
- **Manufacturing and supply chain resilience**: Tied to the manufacturing and supply challenge: contract manufacturing, process qualification and quality services address a named risk and the NAGLAZYME charge.
- **Launch readiness for 2027 PDUFA dates**: Tied to the VOXZOGO expansion priority: market access, pricing and launch operations ahead of the February 28, 2027 and May 30, 2027 decisions.
- **Treasury and international order management**: Tied to the higher debt and lumpy international orders: forecasting, credit risk and currency tools help manage government customers and refinancing.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm)

Annual report · 2026-02-26

- BioMarin is a San Rafael, California-based global rare disease biotechnology company (founded 1997) with eight commercial therapies at end-2025 and 3,221 employees as of December 31, 2025.
- FY2025 total revenues were $3,221.3 million (2024: $2,853.9 million); net income fell to $348.9 million from $426.9 million, hit by about $240.0 million of ROCTAVIAN restructuring charges and a $221.0 million IPR&D charge for Inozyme.
- VOXZOGO (achondroplasia) is the largest product at $926.9 million of 2025 net product revenues, up $191.8 million; VIMIZIM $792.1 million, NAGLAZYME $485.4 million, PALYNZIQ $433.3 million.
- Commercial organization is built around two business units, Skeletal Conditions (VOXZOGO) and Enzyme Therapies; the company reports one operating segment.
- December 2025: agreement to acquire Amicus Therapeutics for $14.50 per share in cash (about $4.8 billion), adding therapies for Fabry and late-onset Pompe disease; financed with cash and about $3.7 billion of debt, including $850.0 million of 5.5% notes due 2034 issued in February 2026.
- ROCTAVIAN (hemophilia A gene therapy) is being voluntarily withdrawn from the market; KUVAN keeps losing revenue to generics ($99.6 million, down $21.3 million).
- Pipeline: VOXZOGO in hypochondroplasia (pivotal Phase 3) and other short-stature conditions, BMN 333 long-acting CNP, BMN 351 for Duchenne, BMN 401 for ENPP1 deficiency.
- Key risks: VOXZOGO competition (Ascendis, BridgeBio's QED and others) and patent litigation, Amicus integration and cost savings, higher debt, pricing reform (IRA), tariffs, international government order timing and currency (37% of net product revenue from three customers).

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm)

Interim report · 2026-11-03

- Q3 2026 total revenues were $1,024.6 million (Q3 2025: $776.1 million); nine-month revenues $2,780.6 million (2025: $2,346.7 million).
- The quarter was a net loss of $122.8 million, driven by $287.7 million of acquired IPR&D for BMN 440, $99.5 million of intangible amortization and $55.6 million of interest expense after the Amicus deal; nine-month net income $27.5 million.
- Amicus Therapeutics was acquired on April 27, 2026 (about $5.3 billion of consideration), adding GALAFOLD (Fabry; Q3 $151.8 million) and POMBILITI + OPFOLDA (Pompe; Q3 $48.6 million). Enzyme Therapies was renamed Metabolic Conditions.
- VOXZOGO Q3 revenue $245.0 million (up $26.6 million), growth mainly outside the U.S.; VIMIZIM $215.8 million, NAGLAZYME $107.8 million, PALYNZIQ $111.0 million.
- Alesta Therapeutics (Netherlands) acquired August 31, 2026 for $303.4 million, adding oral BMN 440 for hypophosphatasia; BMN 401 discontinued in all indications; BMN 450 Fabry enzyme licensed from GC Biopharma and Hanmi ($70.0 million upfront).
- VOXZOGO PDUFA dates: February 28, 2027 (full approval in achondroplasia) and May 30, 2027 (hypochondroplasia); all patent litigation with Ascendis settled in September 2026 for royalties.
- Debt rose to about $4.2 billion at September 30, 2026 (from about $1.5 billion at March 31, 2026); cash fell to $736.0 million.
- Gross margin 80.0% in Q3 (81.9% a year earlier) on mix of lower-margin products.

### [BioMarin Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/11/02/biomarin-bmrn-q3-2026-earnings-call-transcript/)

Executive talk · Alexander Hardy, Chief Executive Officer · 2026-11-02

- CEO Alexander Hardy: Q3 2026 revenue grew 32% year over year and passed $1 billion in a quarter for the first time in BioMarin's history.
- Metabolic Conditions revenue was $744 million, up 44%, driven by the first full quarter of Galafold ($152 million) and Pombiliti + Opfolda ($49 million); Amicus cost synergies are ahead of schedule, with about $220 million of non-GAAP cost synergies expected fully in 2028.
- CFO Brian Mueller: full-year 2026 revenue guidance cut to $3.8-3.9 billion because one international customer intends to defer about $70 million of orders, plus Middle East disruption; non-GAAP EPS guidance $2.80-3.10 after two business development deals.
- VOXZOGO revenue $245 million, up 12%; children treated up about 17%; more than 75% of Q3 revenue came from outside the U.S.; about 85% of U.S. children remained on therapy.
- VOXZOGO hypochondroplasia PDUFA date is May 30, 2027, for an estimated global addressable population of about 14 thousand children.
- Pipeline: four new assets in 2026, including BMN-450 (potential first subcutaneous Fabry enzyme therapy) and BMN-440 (oral therapy for hypophosphatasia, data in 2027); BMN-333 dose-ranging growth data next year.
- Hardy: business development stays focused on clinical-stage deals that fit Skeletal Conditions and Metabolic Conditions.

### [BioMarin Q1 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/05/04/biomarin-bmrn-q1-2026-earnings-transcript/)

Executive talk · Alexander Hardy, Chief Executive Officer · 2026-05-04

- CEO Alexander Hardy: the Amicus acquisition closed the week before the call, adding Galafold (Fabry) and Pombiliti + Opfolda (Pompe) and lifting expected 2026 revenue growth to 20% at the midpoint.
- Q1 2026 total revenues were $766 million; Enzyme Therapies grew 6%; a $31 million NAGLAZYME manufacturing charge hit cost of sales; non-GAAP diluted EPS $0.76.
- Updated 2026 guidance: total revenue $3.825-3.925 billion, Enzyme Therapies $2.725-2.775 billion (about 30% growth), VOXZOGO $975 million-$1.025 billion, non-GAAP EPS $4.85-5.05.
- Amicus is slightly dilutive in 2026, accretive in the first twelve months after closing and "substantially accretive beginning full year 2027"; peak revenue of roughly $1 billion each for Galafold and Pombiliti + Opfolda "has some potential to be higher".
- VOXZOGO: children treated up more than 20% year over year as a competitor entered the U.S.; over half of U.S. new starts under age two; present in 55 countries; full-approval sNDA submitted.
- Pipeline: hypochondroplasia and BMN 401 pivotal readouts in Q2 2026; BMN 333 Phase 2/3 enrolling for a superiority design against VOXZOGO; BMN 351 for Duchenne showed dose-dependent dystrophin increases.
- Hardy on the Ascendis ITC case: enforcing the patent is "the most expeditious way to protect our IP in the United States".

## Questions about BioMarin Pharmaceutical Inc.

### What does BioMarin Pharmaceutical do?

BioMarin develops and sells medicines for rare, genetically defined diseases, including VOXZOGO for achondroplasia and enzyme therapies such as VIMIZIM, NAGLAZYME, PALYNZIQ and GALAFOLD.

### What is BioMarin's revenue?

FY2025 total revenues were $3,221.3 million. Q3 2026 revenues were $1,024.6 million, and FY2026 guidance is $3.8-3.9 billion.

### How many employees does BioMarin have?

BioMarin had 3,221 employees at December 31, 2025, of which 2,026 in the U.S. and Canada and 1,195 outside North America, before the Amicus acquisition.

### What is BioMarin's strategy?

Grow in rare disease through internal research and acquisitions, organized around Skeletal Conditions and Metabolic Conditions, integrate Amicus and extend VOXZOGO to new short-stature conditions.

### Who leads BioMarin?

Alexander Hardy is Chief Executive Officer and Brian Mueller is Chief Financial Officer; Cristin Hubbard is Chief Commercial Officer and Gregory Friberg is Chief R&D Officer.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
